Potential Drug Interactions in Cancer Patients on Oral Kinase Inhibitors

경구용 활성효소 억제제 복용 암환자의 잠재적 약물상호작용 연구

  • Jung, Eun-Hee (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Bang, Joon Seok (Department of Clinical Pharmacy, College of Pharmacy, Chosun University) ;
  • Lee, Yu Jeung (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University)
  • 정은희 (숙명여자대학교 임상약학대학원) ;
  • 방준석 (조선대학교 약학대학) ;
  • 이유정 (강원대학교 약학대학)
  • Received : 2013.02.04
  • Accepted : 2013.06.11
  • Published : 2013.06.30

Abstract

Objectives: Among many new drugs that are under investigation with intent to treat cancer, oral kinase inhibitors are proven to be effective in numerous clinical trials and easy to administer. Due to these advantages the use of oral kinase inhibitors is increasing. Oral kinase inhibitors are metabolized by CYP450 which can result either increase of adverse effect or decrease of drug effect by drug interaction when used concurrently with other agents. In this research, the medication records of patients on oral kinase inhibitors from Oct. 2010 to Nov. 2011 were reviewed to investigate potential drug interactions. Methods: From Oct. 2010 to Nov. 2011, cancer patients in Inha University Hospital who took oral kinase inhibitors more than once were included. The patients' medication records were reviewed to list out concurrent medications that have interaction potential with oral kinase inhibitors, the frequency of concurrent use, and the severity of interaction result using Micromedex$^{(R)}$ and Lexicomp-online$^{(R)}$ as references. Results: As a result, 90 cases of drug with interaction potential were prescribed by Micromedex$^{(R)}$ and 179 cases by Lexicomp-online$^{(R)}$ data. In case of severity, 33.3% by Micromedex$^{(R)}$ and 26.3% by Lexicomp-online$^{(R)}$ were categorized as Major and 65.6% by Micromedex$^{(R)}$ and 72.6% by Lexicomp-online$^{(R)}$ as Moderate. The number of adverse events was 92 cases which 58.7% were on skin and 19.6% on Gastro-intestinal tract. Conclusions: Considerable number of drug with interaction potential was used though each oral kinase inhibitors showed differences in extent. Hence there exists the risk of drug interaction in patients taking oral kinase inhibitors with other drugs.

Keywords

References

  1. Arora A, Scholar EM. Role of Tyrosine Kinase Inhibitors in Cancer Therpy. J Pharmachol Exp Ther 2005; 315(3): 971-9. https://doi.org/10.1124/jpet.105.084145
  2. Steeghs N, Nortier JW, Gelderblom H. Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments. Ann Surg Oncol 2007; 14(2): 942-53. https://doi.org/10.1245/s10434-006-9227-1
  3. Capizzi RL, Keiser LW, Sartorelli AC. Combination Chemotherapy-theory and practice. Semin Oncol 1977; 4(2): 227-53.
  4. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6(7):546-58. https://doi.org/10.1038/nrc1887
  5. Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35(8): 692-706. https://doi.org/10.1016/j.ctrv.2009.08.004
  6. 홍경자, 이석용. 약물상호작용의 이해. 2003, 신일상사
  7. Hartmann JT, Haap M, Kopp HG, et al., Clinical pharmacokinetics of tyrosine kinase inhibitors. Curr Drug Metab 2009; 10: 470-81. https://doi.org/10.2174/138920009788897975
  8. Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H. 2011 "Effect of Rifampin and Ketoconazole on the pharmacokinetics of nilitinib in healthy participants." J Clin Pharmacol 51(1): 75-83. https://doi.org/10.1177/0091270010367428
  9. van Leeuwen, Swart EL, Boven E, et al., Potential drug interaction in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011; 22: 2334-41. https://doi.org/10.1093/annonc/mdq761
  10. Guastaldi RB, Resi AM, Figueras A, Secoli SR. 2011 "Prevalence of potential drug-drug interactions in bone marrow transplant patients." Int J Clin Pharm 33(6): 1002-9. https://doi.org/10.1007/s11096-011-9574-2
  11. World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2012. http:// www.whocc.no/atcddd/index. (accessed on May 1, 2012)
  12. Thompson Reuters Micromedex(R)2.0. http://www.thomsonhc. com/micormedex2 .(Accessed on May 1, 2012)
  13. Lexi-interact TM Online. http://www/uptodate.com/crlsql/ interact/fra,eset.jsp .(Accessed on May 1, 2012)
  14. Ogawa R, Echizen H. Clinically significant drug interactions with antacid: an update. Drugs 2011; 71: 1839-64. https://doi.org/10.2165/11593990-000000000-00000
  15. Eley T, Luo FR, Agrawal S, et al., Phase 1 study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009; 49: 700-9. https://doi.org/10.1177/0091270009333854
  16. Sparano BA, Egorin MJ, Parise RA, et al., Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009; 63: 525-8. https://doi.org/10.1007/s00280-008-0778-7
  17. Tarceva prescribing information. Genetech, http://gene.com/ gene/products/information/oncology/tarceva. (Accessed on May 1, 2012).
  18. Iressa product information. Astrazeneca. http://www.iressa.com/product-information. (Accessed on May 3, 2012).
  19. Writht A, Feblowitz J, Phansalkar S, et al., Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. Am J Health Syst Pharm 2012; 69: 221-7. https://doi.org/10.2146/ajhp110084
  20. Midyear Clinical Meeting supplemental handout. ASHP 2009. Drug Interaction Alerts: The Battle against alert fatigue. http://www.ashp.org/DocLibrary/MemberCenter/ SPPM/ManagePearls/MCM09-223-16-Handout-Lee.aspx. (Accessed on May 3, 2012).
  21. ASHP Guidelines on Medication-Use-Evaluation. 1996. http://www.ashp.org/DocLibrary/BestPractices/FormGdlmed UseEval.aspx (Accessed on May 1, 2012).
  22. Moura CS, Prado NM, Belo NO, et al., Evaluation of drugdrug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 2012; (DOI:10.1007/s11096-012-9642-2).
  23. Hartmann JT, Happ M, Kopp HG, et al., Tyrosine Kinase Inhibitors-A Review on Pharmacology, Metabolism and Side Effects. Curr Drug Metab 2009; 10: 470-81. https://doi.org/10.2174/138920009788897975
  24. Gleevec product information. Norvatis. http://www.gleevec. com/health-care-professional. (Accessed on May 3, 2012).
  25. Tykerb product information. GSK. http://www.tykerb.com (Accessed on May 3, 2012).
  26. Nexavar product information. Bayer. http://www.nexavarinternational. com/home/important_safety_considerations,php. (Accessed on May 1, 2012).
  27. Sutent prescribing information. Pfizer. http://www.pfizer. com/files/products/uspi_sutent/pdf (Accessed on May 1, 2012).